Leerink Partners Maintains Outperform on Regenxbio, Raises Price Target to $18
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Leerink Partners analyst Mani Foroohar maintains Regenxbio (NASDAQ:RGNX) with a Outperform and raises the price target from $17 to $18.
Leerink Partners analyst Mani Foroohar maintains Regenxbio (NASDAQ:RGNX) with a Outperform and raises the price target from $17 to $18.